

HUTCHMED

Delivering on sharpened goals and priorities

1 August 2023

- HUTCHMED remains focused on its goal of near-term value creation and building a self-sustaining business that achieves profitability in FY25. H123 results show the twin impacts of revenue growth driven by commercial execution in China and cost reduction due to late-stage portfolio and registration study prioritisation. HUTCHMED's global partnering approach, which included the up to \$1.13bn Takeda deal for global ex-China rights to fruquintinib ([January 2023 Lighthouse](#)), boosted both top and bottom lines.
- The focus Oncology/Immunology segment reported consolidated revenues of \$359m (+294%, \$91.1m) consisting of \$100.5m (H122: \$76.1m) from product sales/R&D services and \$258.7m (H122: \$15m) from partnering income. Total H123 revenues were \$533m (+164%, H122: \$202m), including Other Ventures of \$173.7m (+57%, \$110.9m). Portfolio optimisation reduced R&D spend by 20% to \$144.6m (H122: \$181.7m), while the restructuring of US operations contributed to lower SG&A of \$68.3m (H122: \$79.7m). Net income from Other Items of \$56.9m (vs \$33.9m) reflected higher interest income and FX gains. Net Income was \$168.6m vs a Net Loss in H122 of \$258.7m. End-H123 cash of \$856m (end-FY22: \$631m) includes the \$400m Takeda upfront payment.
- Revenue from oncology products in China, coupled with partial recognition (\$280m) of the Takeda upfront, contribute to unchanged FY23 revenue guidance of \$450-550m. HUTCHMED's three approved China products - Elunate (fruquintinib), Sulanda (surufatinib), Orpathys (savolitinib) - are now all included on the NRD and together have shown solid in-market sales growth of 16% (25% at CER), with volume growth offsetting any pricing discounts.
- HUTCHMED is also driving its pipeline, with 15+ registration/registration-intent studies in progress with seven drug candidates. Key H223 catalysts include the outcome of the FDA review of fruquintinib in advanced metastatic colorectal cancer ([June 2023 Update](#)) by or on the 30 November PDUFA goal date, and potential China NDA filings of the first haem-oncology assets, sovleplenib (a Syk inhibitor) for 2L immune thrombocytopenia (ITP) and PI3Kδ inhibitor amdisalisib in 3L follicular lymphoma, subject to positive results from ongoing registration-intent studies during H223.

Price (US ADS)	\$14.07
(UK share)	223.25p
(SEHK share)	HK\$23.75
Market Cap	US\$2.43bn £1.93bn HK\$20.57bn
Exchanges	NASDAQ AIM London SEHK
Sector	Healthcare
Company codes	HCM HCM.L 0013.HK
Corporate client	Yes

Company description:

HUTCHMED is a Hong Kong headquartered biopharma focused on discovering, developing and commercialising innovative targeted therapeutics and immunotherapies to treat cancer and autoimmune diseases. It has a diverse pipeline of first-in-class/best-in-class selective oral TKIs in development for the China and global markets.

Analysts

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Philippa Gardner

pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Trinity Delta view: HUTCHMED's path to profitability is supported by growing traction and market share capture of its China oncology products, potential launch (by partner Takeda) of the first HUTCHMED discovered and developed drug ex-China, and a solid balance sheet. As fruquintinib is a material near-term opportunity ex-China, investors are understandably focused on its November PDUFA date, this should be followed by a European EMA decision in 2024 (Japan PDMA submission is expected this year). A second global asset, savolitinib, is completing multiple pivotal trials with potential for filing(s) in 2024. HUTCHMED is also on the cusp of first China filing(s) for its second-wave haem-oncology assets and we expect these to feature in the Q423 Capital Markets Day. Our last published valuation of US\$5.5bn (US\$32.01 per ADS), £4.6bn and HK\$43.2bn (534p or HK\$49.94 per share), does not yet reflect the interim results and business update.

Philippa Gardner

pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Franc Gregori

fgregori@trinitydelta.org
+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2023 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org